Clinical Trial Details
LY2875358 + Erlotinib & LY2875358 Monotherapy, MET Positive NSCLC w/ Resistance to Erlotinib Official Title:
LY2875358 + Erlotinib & LY2875358 Monotherapy, MET Positive NSCLC w/ Resistance to Erlotinib
Start Date August 16, 2013
End Date November 1, 2014
| Gender Preference |
|None|| Age Group |
|18 - 99 years|
| Principal Investigator |
|Taher Abu Hejleh, MD|
| Contact Info |
Susan Gillen, 319-467-5827
|Department or Field of Study|
The purpose of this study is to test the effectiveness of the research study drugs LY2875358 and erlotinib in making tumors smaller in patients with metastatic non-small cell lung cancer.
This is a research study to test the effectiveness of LY2875358 and erlotinib, also known as “investigational.” This means the drug has not been approved by the U.S. Food and Drug Administration (FDA) for the use described in this study. However, the FDA has allowed the use of this drug for research.
About 100 people will be enrolled in the study.
|201307502 ; cancer ; Clamon ; NSCLC ; Phase 2 ; |